Researchers identified a handful of prognostic factors to create a synthetic control arm, which can ultimately replace placebo control arms in future trials of salvage-line metastatic CRC.
Adding liver metastases status to tumor sidedness may enhance first-line targeted treatment selection in certain patients with metastatic colorectal cancer.